Swiss authorised representative (CH-REP): when is one required, and what does it do?
Who must appoint an authorised representative in Switzerland, what the written mandate has to cover, what the CH-REP answers for (vigilance, technical documentation, joint and several liability), its registration and CHRN, labelling and the designation deadlines, article by article from the MedDO, the IvDO and the TPA.
By Iohannès Bry · Updated on November 15, 2026 · 10 min read
In short. A manufacturer that is not domiciled in Switzerland may place its devices on the Swiss market only once it has designated an authorised representative domiciled in Switzerland by means of a written mandate (Art. 51 para. 1 MedDO; Art. 44 para. 1 IvDO); this applies to manufacturers established in the EU or EEA as well (Swissmedic information sheet MU600_00_016, section 3), and a manufacturer based in Liechtenstein does not have to designate one, under the customs treaty (MU600, section 6). The authorised representative, which Swissmedic abbreviates as CH-REP, is responsible for the formal and safety-related aspects of placing the device on the market, reports serious incidents in Switzerland to Swissmedic and is jointly and severally liable with the manufacturer for damage (Art. 51 para. 2 and Art. 66 para. 2bis MedDO; Art. 47d TPA). It registers with Swissmedic before the first placing on the market and receives a CHRN (Art. 55 MedDO); the designation deadlines granted to EU and EEA manufacturers all expired by 31 July 2023 at the latest (Art. 104a MedDO; Art. 86 IvDO).
Who must appoint an authorised representative
An authorised representative is any natural or legal person established in Switzerland that has received a written mandate from a manufacturer domiciled abroad to act on its behalf in relation to specified tasks linked to the manufacturer's obligations under the Ordinance (Art. 4 para. 1 let. g MedDO).
| Manufacturer's situation | Swiss authorised representative | Legal basis |
|---|---|---|
| Domiciled in Switzerland | Not required: the obligation targets manufacturers not domiciled in Switzerland | Art. 51 para. 1 MedDO |
| Domiciled in the EU or EEA | Required | Art. 51 para. 1 MedDO; MU600, section 3 |
| Domiciled in any other country | Required | Art. 51 para. 1 MedDO |
| Domiciled in Liechtenstein | Not required, under the customs treaty between Switzerland and Liechtenstein | MU600, section 6 |
| Person assembling systems and procedure packs, not domiciled in Switzerland | Required, mutatis mutandis | Art. 51 para. 5 MedDO |
| IVD manufacturer not domiciled in Switzerland | Required, same rule | Art. 44 para. 1 IvDO |
A foreign manufacturer does not have to register as an operator in Switzerland itself (it does not apply for a CHRN): it appoints an authorised representative, and the representative registers (swissdamed FAQ). According to Swissmedic, the designation covers at least all devices of the same generic device group (MU600, section 3, with Art. 51 para. 3 MedDO and Art. 11(2) MDR).
The written mandate
The mandate must be agreed in writing (Art. 51 para. 1 MedDO; Art. 44 para. 1 IvDO). Several points have to be settled in it:
- Scope: the representative's rights and obligations, and the scope of the mandate, are governed by Article 11 MDR (Art. 51 para. 3 MedDO) or Article 11 IVDR (Art. 44 para. 3 IvDO).
- Change of representative: governed by Article 12 MDR (Art. 51 para. 4 MedDO) or Article 12 IVDR (Art. 44 para. 5 IvDO).
- Vigilance: transferring the reporting obligations to the representative must be agreed in writing in the mandate (Art. 66 para. 2bis MedDO; Art. 59 para. 3 IvDO).
- Technical documentation: instead of the representative keeping a copy available, the parties may agree that the manufacturer submits it straight to Swissmedic on request; the representative must then ensure that it is submitted within seven days (Art. 51 para. 3bis MedDO; Art. 44 para. 4 IvDO).
In swissdamed, the mandate is a record of its own: without a valid mandate, no device may be placed on the Swiss market, and when a mandate is deactivated its UDI-DIs switch to the status "No longer placed on the market" (swissdamed FAQ, Actors module, "Mandate").
What the authorised representative answers for
| Obligation | What the text says | Legal basis |
|---|---|---|
| Placing on the market | Responsible for the formal and safety-related aspects of placing the device on the market | Art. 51 para. 2 MedDO; Art. 44 para. 2 IvDO |
| Technical documentation | Copy kept available, or submission by the manufacturer to Swissmedic ensured within seven days | Art. 51 para. 3bis MedDO; Art. 44 para. 4 IvDO |
| Person responsible for regulatory compliance | Permanently and continuously at its disposal | Art. 52 para. 1 MedDO; Art. 45 para. 1 IvDO |
| Vigilance | Reports serious incidents and field safety corrective actions in Switzerland, submits trend reports unprompted | Art. 66 para. 2bis MedDO; Art. 59 para. 3 IvDO |
| Economic operator registration | Before the first placing on the market; Swissmedic assigns the CHRN | Art. 55 paras 1 and 4 MedDO; Art. 48 paras 1 and 4 IvDO |
| Device registration | Registers the mandated devices in the swissdamed UDI Devices module | Swissmedic page "Device registration" |
| Liability | Sufficient financial cover (manufacturer or representative); joint and several liability with the manufacturer | Art. 47d paras 1 and 2 TPA |
The person responsible for regulatory compliance
The authorised representative must have permanently and continuously at its disposal at least one person with the requisite expertise in the requirements for medical devices under the MedDO (Art. 52 para. 1 MedDO; Art. 45 para. 1 IvDO). In other respects the manufacturer's rules apply mutatis mutandis: expertise, a deputy in place, a written division of responsibilities where there are several such persons, and no disadvantage for the person designated (Art. 52 para. 2 MedDO, referring to Art. 49 paras 2 to 4, which in turn refers to Article 15 MDR).
Vigilance
Where an authorised representative is required under Article 51, it is responsible for reporting to Swissmedic serious incidents that occurred in Switzerland and field safety corrective actions undertaken in Switzerland; it also submits trend reports without being asked (Art. 66 para. 2bis MedDO; Art. 59 para. 3 IvDO).
Liability and financial cover
The manufacturer or the authorised representative must have sufficient financial cover for damage caused by defective medical devices, and the representative and the manufacturer are jointly and severally liable for that damage (Art. 47d paras 1 and 2 TPA).
Registration: the CHRN and swissdamed
Authorised representatives and importers do not need an authorisation from Swissmedic: they only have to register (MU600, section 8, question a). Swissmedic checks the data submitted and assigns a Swiss Single Registration Number (CHRN) (Art. 55 para. 4 MedDO; Art. 48 para. 4 IvDO): it is a registration, not an authorisation.
- Economic operator registration has been mandatory in Switzerland since 26 November 2021 and has been done in swissdamed since August 2024 (Swissmedic page "Device registration"); the current wording of Art. 55 para. 1 MedDO, which places it before the first placing on the market, has applied since 1 July 2026.
- One CHRN per role: a company that is both importer and CH-REP fulfils both sets of obligations and receives two different CHRNs (swissdamed FAQ; MU600, section 8, question g).
- The European SRN issued through EUDAMED does not replace the CHRN (swissdamed FAQ).
- Swissmedic has in principle 30 days at most to process an application; if it raises objections, the period restarts once the file is complete, and an application not completed within 30 days of the objection is rejected (swissdamed FAQ).
- Assigning a CHRN costs CHF 200 (SR 812.214.5, Annex 2 No 5).
| When | What is due | Legal basis |
|---|---|---|
| Before the first placing on the market | Register the economic operator with Swissmedic | Art. 55 para. 1 MedDO; Art. 48 para. 1 IvDO |
| Within one week of any change | Report the change to the operator's data | Art. 55 para. 2 MedDO; Art. 48 para. 2 IvDO |
| Immediately | Register a device for which a serious incident, a field safety corrective action or a trend must be reported (devices placed on the market since 26 May 2021; IVDs, since 26 May 2022) | Art. 108 para. 3 MedDO; Art. 90 para. 2bis IvDO |
| 31 December 2026 | Register in swissdamed the devices placed on the market from 1 July 2026, and those already on the market of which further units are sold afterwards | Art. 108 para. 2 MedDO; Art. 90 para. 2 IvDO; swissdamed FAQ |
| From 1 January 2027 | The CH-REP ensures that the devices it represents are registered in swissdamed | MU600, section 5 |
For a foreign manufacturer, the invoice for device registration fees is sent to the CH-REP, with a separate invoice for each mandate (Swissmedic page "Registration fees"; information sheet BW630_40_001, section 5.2.3).
What the importer checks
Before placing a device on the market, the importer checks that the manufacturer is identified and has mandated a person in accordance with Article 51 (Art. 53 para. 1 let. c MedDO; Art. 46 para. 1 let. c IvDO).
Labelling: where the representative appears
| Device | Where the CH-REP details go | Legal basis |
|---|---|---|
| MDR device | On the label | MU600, section 6 (Swissmedic's reading of Art. 16 para. 1 MedDO) |
| IVD not intended for self-testing, other than legacy devices | On the label or on a document accompanying the device | Art. 15 para. 9 IvDO, in force since 1 January 2025 |
| IVD for self-testing | On the label | MU600, section 6 |
The tolerance that allowed the representative's details to be given on an accompanying document for class I devices, systems and procedure packs ended on 31 July 2023 (Art. 104abis MedDO). Devices placed on the market under the former directives follow rules of their own, set out in the same section of the information sheet.
The designation deadlines, all expired
A manufacturer domiciled in the EU or EEA, or which had designated an authorised representative domiciled there, was given time to designate its Swiss representative for devices placed on the market after 26 May 2021 (Art. 104a para. 1 MedDO) and, for IVDs, from 26 May 2022 (Art. 86 IvDO). All of these deadlines have passed: today, no representative means no placing on the market.
| Devices | Designation no later than | Legal basis |
|---|---|---|
| Class III, implantable class IIb, active implantable medical devices | 31 December 2021 | Art. 104a para. 1 let. a MedDO |
| Non-implantable class IIb, class IIa | 31 March 2022 | Art. 104a para. 1 let. b MedDO |
| Class I | 31 July 2022 | Art. 104a para. 1 let. c MedDO |
| Systems and procedure packs | 31 July 2022 | Art. 104a para. 2 MedDO |
| Class D IVDs | 31 December 2022 | Art. 86 let. a IvDO |
| Class B and C IVDs | 31 March 2023 | Art. 86 let. b IvDO |
| Class A IVDs | 31 July 2023 | Art. 86 let. c IvDO |
In a Normiq pathway
The Switzerland and EU + Switzerland pathways for medical devices and IVDs include the designation of the Swiss authorised representative and the registration of the economic operator with Swissmedic among their steps. The page "What Switzerland adds to a CE file" places them class by class, and the swissdamed page details device registration, role by role.
Sources
- Medical Devices Ordinance (MedDO, SR 812.213), version of 1 July 2026 (unofficial English translation)
- Ordinance on In Vitro Diagnostic Medical Devices (IvDO, SR 812.219), version of 1 July 2026 (unofficial English translation)
- Therapeutic Products Act (TPA, SR 812.21), Art. 47d (French version)
- Swissmedic Fees Ordinance (SR 812.214.5), Annex 2 (French version)
- Swissmedic, information sheet MU600_00_016 on the obligations of economic operators, v8.0 of 26 October 2026 (French version)
- Swissmedic, swissdamed: questions and answers (French version)
- Swissmedic, swissdamed: device registration (French version)
- Swissmedic, swissdamed: registration fees (French version)
- Swissmedic, information sheet BW630_40_001 on device registration fees (French version)
Read next
From the text to your device's roadmap
Normiq places every requirement in your device's roadmap, with the steps that lead to it. Free 7-day trial.
Start the free trial